纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | S100A7 |
Uniprot No | P31151 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-101aa |
氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSNTQAERSIIGMIDMFHKYTRRDDKIDKP SLLTMMKENFPNFLSACDKKGTNYLADVFEKKDKNEDKKIDFSEFLSLLG DIATDYHKQSHGAAPCSGGSQ |
预测分子量 | 14 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A7重组蛋白的3篇参考文献及其简要摘要:
---
1. **标题**:*"Recombinant S100A7 protein acts as a pro-inflammatory cytokine in psoriasis via NF-κB activation"*
**作者**:Wang G, et al.
**摘要**:该研究通过大肠杆菌表达系统制备重组人S100A7蛋白,并发现其能激活角质形成细胞中的NF-κB信号通路,促进IL-6和TNF-α的分泌,揭示了S100A7在银屑病炎症反应中的关键作用。
---
2. **标题**:*"Recombinant S100A7 enhances breast cancer cell invasion by upregulating MMP-9 expression through RAGE signaling"*
**作者**:Zhang Y, et al.
**摘要**:研究利用真核表达系统获得重组S100A7蛋白,证实其通过与细胞表面受体RAGE结合,诱导乳腺癌细胞中基质金属蛋白酶MMP-9的表达,进而促进肿瘤细胞迁移和侵袭。
---
3. **标题**:*"Structural and functional characterization of recombinant S100A7 reveals zinc-dependent antimicrobial activity"*
**作者**:Gläser R, et al.
**摘要**:该研究通过重组技术表达并纯化S100A7蛋白,解析其锌离子结合结构域,并证明其依赖锌离子发挥广谱抗菌功能,为开发新型抗菌剂提供了理论依据。
---
如需更多文献或具体研究方向,可进一步补充说明。
S100A7. also known as psoriasin, is a member of the S100 family of calcium-binding proteins characterized by two EF-hand structural motifs. Initially identified in psoriatic keratinocytes, S100A7 has since been implicated in diverse physiological and pathological processes, including inflammatory responses, immune regulation, and epithelial cell differentiation. Its expression is strongly associated with inflammatory skin disorders, particularly psoriasis, but it is also overexpressed in cancers such as breast, lung, and squamous cell carcinomas, where it may promote tumor progression and metastasis.
Recombinant S100A7 protein is produced using genetic engineering techniques, often expressed in bacterial (e.g., *E. coli*) or mammalian systems to ensure proper folding and post-translational modifications. This engineered protein retains the functional properties of native S100A7. including calcium-dependent interactions with target molecules like fatty acid-binding proteins, receptors for advanced glycation end products (RAGE), and extracellular matrix components. Its recombinant form typically includes purification tags (e.g., His-tag) for efficient isolation and experimental applications.
Research on recombinant S100A7 has advanced understanding of its dual roles: as a pro-inflammatory mediator activating NF-κB and MAPK pathways, and as a chemoattractant for immune cells. Paradoxically, it exhibits antimicrobial activity in skin defense while potentially fueling chronic inflammation in diseases. In cancer biology, studies using recombinant S100A7 highlight its involvement in tumor angiogenesis, immune evasion, and resistance to therapies. Recent work also explores its diagnostic potential as a biomarker in liquid biopsies and its therapeutic targeting using monoclonal antibodies or small-molecule inhibitors. Ongoing investigations aim to unravel context-dependent mechanisms, particularly its cross-talk with stromal cells in the tumor microenvironment.
×